p = 0.01), and semaglutide (OR = 0.38
see in-text citations
Tirzepatide targets both GLP-1R and the glucose-dependent insulinotropic peptide receptor (GIPR), while the older two medications focus on GLP-1R alone
Most overweight individuals are vitamin D deficient to begin with, and reduced food intake can worsen this
Estos frmacos incluyen semaglutida (Ozempic, Wegovy, Rybelsus), dulaglutida (Trulicity), liraglutida (Victoza, Saxenda), mientras que tirzepatida (Mounjaro, Zepbound) es un agonista dual GIP/GLP-1, no un agonista GLP-1 puro
The truth is, once the medication stops, the weight will likely creep back on if nothing else changes (as seen in studies)